DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aromasin (Exemestane) - Current Clinical Trials

 
 



Aromasin Related Clinical Trials

Aromasin´┐Ż Non-Interventional Study Of Early Invasive Breast Cancer Patients In China [Recruiting]

An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin [Terminated]

A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin´┐Ż) In Postmenopausal Hr+ Patients [Terminated]

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding [Completed]

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer [Completed]

Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin [Completed]

Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects [Suspended]

A Non-Interventional Study With Aromasin« As Adjuvant Treatment Of Invasive Early Breast Cancer [Terminated]

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer [Recruiting]

Adjuvant Post-Tamoxifen Exemestane Trial [Terminated]

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane [Completed]

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer [Completed]

Exemestane-RAD001-Metformin [Active, not recruiting]

Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer [Completed]

Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant [Completed]

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer [Active, not recruiting]

Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer [Recruiting]

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD [Recruiting]

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients [Terminated]

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer [Withdrawn]

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer [Completed]

Exemestane in Advanced and Recurrent Endometrial Carcinoma [Completed]

Aromasin´┐Ż As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer [Terminated]

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen [Completed]

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer [Completed]

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer [Not yet recruiting]

Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors [Recruiting]

Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer [Completed]

An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis [Active, not recruiting]

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer [Active, not recruiting]

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer [Completed]

Exemestane With Sunitinib (SUTENT«) in Metastatic Breast Cancer [Terminated]

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer [Completed]

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer [Active, not recruiting]

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer [Terminated]

Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer [Recruiting]

Exemestane and Cyclophosphamide for Metastatic Breast Cancer [Active, not recruiting]

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer [Active, not recruiting]

Therapeutic Estradiol and Exemestane in Treating Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer [Active, not recruiting]

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer [Recruiting]

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women [Terminated]

The Impact of Obesity and Obesity Treatments on Breast Cancer [Completed]

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease [Completed]

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer [Not yet recruiting]

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer [Recruiting]

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer [Recruiting]

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) [Active, not recruiting]

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab [Recruiting]

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) [Completed]

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions [Completed]

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer [Terminated]

Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions [Completed]

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions [Completed]

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer [Completed]

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors [Active, not recruiting]

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer [Active, not recruiting]

Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer [Completed]

Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer [Recruiting]

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy [Active, not recruiting]

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) [Completed]

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients [Completed]

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer [Completed]

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery [Active, not recruiting]

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer [Terminated]

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors [Recruiting]

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. [Active, not recruiting]

A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer [Completed]

Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer [Active, not recruiting]

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer [Active, not recruiting]

Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer [Completed]

Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer [Recruiting]

Phase III Study of Palbociclib (PD-0332991) in Combination With Exemestane Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Non-steroidal Aromatase Inhibitors [Recruiting]

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer [Recruiting]

Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer [Recruiting]

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer [Recruiting]

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer [Terminated]

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer [Completed]

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer [Withdrawn]

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer [Active, not recruiting]

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer [Terminated]

A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients [Recruiting]

Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles [Recruiting]

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer [Terminated]

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen [Completed]

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer [Completed]

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer [Active, not recruiting]

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer [Completed]

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer [Terminated]

ELBA: Exemestane and Lapatinib in Advanced Breast Cancer [Withdrawn]

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) [Completed]

A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer [Completed]

Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer [Terminated]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015